Skip to main content

new paths to better therapies.

Advancing small-molecule discovery through proprietary computational technologies and molecular biology for patients, clinicians and pharmaceutical partners.

Bring your target. Build a discovery program.

We welcome research groups, biotech and pharma teams to collaborate on discovery or apply for platform access.

Joint discovery programs

Bring a biological target or an existing molecular series.

  • De novo discovery

    You bring the target. We build the program.

  • Lead optimization

    You bring a series. We work potency and properties.

Free research access

Verified researchers at universities, nonprofits and companies can apply for free core platform access.

Subject to review, available capacity and fair-use limits. Research IP stays with its rights holders; commercial data sharing is not required.

Built to advance therapeutics

Biology, molecular design, computational evidence and the wet lab only work when they inform each other. We run them as one iterative research process.

Our proprietary platform is the engine behind it: scientific reasoning, design and simulation in one place.

Illustrative small molecule bound in a protein pocket

Discovery guided by molecular context.

Target biology

Examine structure, binding pockets and biological mechanism before designing compounds.

Molecular design

Develop candidate series around target interactions, with a rationale for each molecular change.

Computational assessment

Compare binding predictions, molecular properties and ADME estimates to prioritize candidates.

Experimental feedback

Use experimental findings, where available, to refine the next round of molecular design.

Connected workflows. Traceable decisions.

Agentic workflows connect literature, structures, design and analysis. Scientists assess the evidence and decide what to test next.

Illustrative candidate design lineage.

Scroll horizontally to explore the illustrative lineage.

Our therapeutic portfolio.

Proprietary small-molecule programs for future development, partnering, or licensing. We begin with antimicrobial resistance.

Antimicrobial resistance

Early discovery

We investigate small molecules with the potential to complement existing antibiotic therapies. Experimental validation guides what moves forward.

Illustrative view of antimicrobial resistance as a global health challenge

Beyond AMR

Our computational approach can investigate biological targets across therapeutic areas. AMR is our active program; additional programs are exploratory and still ahead of us. We welcome partner-proposed targets and molecular series.

NeoraLab Research

Every program leaves behind mechanistic insight, computational results, and the provenance to reproduce them.

Every discovery builds knowledge.

Computational results, in-silico synthetic data and wet-lab feedback from NeoraLab’s own research build a curated knowledge base.

Each cycle refines our workflows and can help advance frontier models in biology, supporting faster, better research.

Private user research stays protected and under its rights holders’ control.

How we handle research data
neoralab logo

AI generates. Science decides.

We pair scientific reasoning with molecular design, with deep expertise in protein dynamics and allosteric regulation.

AI widens the search. Judgment, traceable evidence and wet-lab validation decide what we advance.

Who we are

We bring together AI engineering, software, molecular biology, and computational research to pursue new small-molecule therapeutics.

Fabio Bove

Fabio Bove

Chief Executive Officer

AI Engineer, Multi-Agent Systems in Drug Discovery

Marco Ferrarini

Marco Ferrarini

Chief Scientific Officer

Computational & Molecular Biologist

Elena Addis

Elena Addis

Scientific Advisor

Clinical Study Coordinator, Microbiology Area

Riccardo Cecchetto

Riccardo Cecchetto

Scientific Advisor

Bioinformatician & Data Analyst with focus on Microbiology

Have a target or a stalled compound series?

We can reassess existing compounds, explore alternative molecular scaffolds, and investigate new target hypotheses. Our computational approach helps identify what may be worth testing next.

Illustrative exploration of molecular scaffolds around a binding pocket
  • Scaffold hopping

    Explore alternative cores while retaining molecular interactions relevant to binding.

  • Series re-evaluation

    Revisit potency, selectivity or physicochemical limitations in existing leads.

  • Drug repurposing

    Assess plausible new target hypotheses for known compounds before experimental testing.

Let's advance therapeutic discovery.

We welcome conversations with pharma and biotech teams, scientific collaborators, and investors.

or write to [email protected]

For a discovery proposal, include a non-confidential overview of your target or molecular series. Please wait for an appropriate agreement before sending confidential research.

We use these details only to reply to you. See our privacy policy.